Cash and cash equivalents were EUR236M as of March 31, compared to EUR281M for December 31, 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
- Pharvaris initiated with an Overweight at Cantor Fitzgerald
- Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
- Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
- Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue